The Zacks Analyst Blog Highlights:TD Ameritrade Holding, Toronto-Dominion Bank, Corcept Therapeutics, Shire and Jazz

  The Zacks Analyst Blog Highlights:TD Ameritrade Holding, Toronto-Dominion
          Bank, Corcept Therapeutics, Shire and Jazz Pharmaceuticals

PR Newswire

CHICAGO, Aug. 13, 2013

CHICAGO, Aug. 13, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include  theTD Ameritrade Holding
Corporation(NYSE:AMTD-Free Report), The Toronto-Dominion Bank(NYSE:TD-Free
Report), Corcept Therapeutics Inc.(Nasdaq:CORT-Free Report),
Shire(Nasdaq:SHPG-Free Report) andJazz Pharmaceuticals(Nasdaq:JAZZ-Free


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Monday's Analyst Blog:

TD Ameritrade's July Trades Rise

Last week,TD Ameritrade Holding Corporation(NYSE:AMTD-Free Report) – an
online brokerage firm – reported a rise in average client trades from the
prior year in its Activity Report for the month of Jul 2013. However, U.S.
trades fell 6% from the prior month levels.

For the reported month, average client trades were 373,000, up 12% year over
year. The rise in client trades largely resulted from a resurgence in the
equity markets.

For the month, TD Ameritrade reported $544.2 billion in total client assets,
up 21% year over year and 4% from the prior month. Moreover, average
spread-based balances increased 18% year over year to $88.2 billion. Further,
these balances nudged up 1% from Jun 2013.

At July-end, average fee-based balances were recorded at $120.6 billion,
rising 33% year over year and 2% from the prior month.

Quarterly Performance

As of Jun 30, 2013, average client trades per day increased 12% year over year
to 399,216. Net new client assets were $10.8 billion, up 11% from $9.7 billion
in the past year.

At the end of June, TD Ameritrade reported total client assets worth $523.5
billion, up 18% year over year. Moreover, average spread-based balance was
$84.7 billion, up 14% from $74.2 billion in the prior-year quarter. Average
fee-based balance was $118.1 billion, up 34% year over year.

Our Viewpoint

Innovations in online trading, long-term investment in products and services,
delivery of advanced customer service, creative as well as cost-effective
marketing and sales, along with prudent expense management are the key factors
behind TD Ameritrade's strategy of boosting its trading and investing

Further, the company's association withThe Toronto-Dominion
Bank(NYSE:TD-Free Report) provides an opportunity to cross-sell its products.
This is expected to be a significant growth driver for TD Ameritrade's organic

Amid a volatile operating environment, TD Ameritrade witnessed a rise in both
organic client assets and trading volumes, which will benefit the company.
However, a low interest rate environment and stringent regulations will likely
be dampeners.

Corcept's Q2 Loss In-Line with Expectations

Corcept Therapeutics Inc.(Nasdaq:CORT-Free Report) posted a loss per share of
11 cents in the second quarter of 2013, in line with the Zacks Consensus
Estimate, but wider than the year-ago loss of 9 cents.

Corcept generated revenues of $1.9 million in the second quarter of 2013,
missing the Zacks Consensus Estimate of $3.0 million. Revenues jumped 116%

The revenues reported in the quarter included a product return reserve of $0.3
million incurred due to the company's transition to a new specialty pharmacy
in addition to government rebates, chargebacks and other allowances.

In Apr 2012, Corcept launched its drug, Korlym, in the U.S. Korlym, is
approved in the U.S. and the EU as a once-daily oral medication for the
treatment of hyperglycemia secondary to hypercortisolism in adults suffering
from endogenous Cushing's syndrome, who have type II diabetes or glucose

We note that Corcept enjoys orphan drug designation for Korlym from the FDA
for the approved indication.

Selling, general and administrative expenses were $8.2 million in the second
quarter of 2013, up 41.3% from the year-ago quarter. The increase was mainly
due to higher staffing, consultancy and other professional services costs
related to the commercialization of Korlym.

Research and development expenses in the second quarter were $4.5 million, up
24.7% in the year-ago quarter. The increase was mainly attributable to the
expansion of the phase III trial on Korlym for the treatment of psychotic
depression along with the development of the company's next-generation
selective GR-II antagonists.

Pipeline Update

Corcept continues to enroll patients for a phase III study on the use of
Korlym for the treatment of psychotic depression. Interim results from the
study are expected in the third quarter of 2014.

Corcept's key objective in 2013 is the successful commercialization of Korlym.

Corcept currently carries a Zacks Rank #3 (Hold). Right
now,Shire(Nasdaq:SHPG-Free Report) andJazz
Pharmaceuticals(Nasdaq:JAZZ-Free Report) are Zacks Rank #2 (Buy) stocks.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on AMTD - FREE

Get the full Report on TD - FREE

Get the full Report on CORT - FREE

Get the full Report on SHPG - FREE

Get the full Report on JAZZ - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.